New combo therapy aims to clear hepatitis b and d in 20-patient trial

NCT ID NCT04638439

Completed Disease control Sponsor: PharmaEssentia Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new treatment approach for adults with chronic hepatitis B or D. Twenty participants received two medications in sequence: P1101 (a type of interferon) followed by an anti-PD1 drug. The main goal was to check safety and tolerability, while also looking for signs that the virus might be cleared, such as loss of hepatitis B surface antigen (HBsAg). The study is now complete.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection hepatitis D virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B INFECTION CHRONIC HEPATITIS D INFECTION

Contacts and locations

Locations

Chang Gung Memorial Hospital, Linkou

Taoyuan City, Taiwan
Chia-Yi Christian Hospital

Chiayi City, Taiwan
National Taiwan University Hospital

Taipei, Taiwan
Taipei Medical University Hospital

Taipei, Taiwan
Taipei Veterans General Hospital

Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.